Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05343065 · ClinicalTrials.gov registry record · NA

A Continuous Glucose Monitor Based Insulin Bolus Calculator (CGM-IBC) Study B

A NA study of Diabetes Mellitus, sponsored by Welldoc.

Completed
Registry status
NA
Development phase
27
Enrollment target
1
Study location

NCT05343065: Completed NA study of Diabetes Mellitus, sponsored by Welldoc.

NCT05343065 is a NA study of Diabetes Mellitus that has completed, run by Welldoc. The registered enrollment target is 27 participants, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05343065, a NA study of Diabetes Mellitus, has completed, sponsored by Welldoc.

COMPLETED
Registry status
NA
Development phase
27 participants
Enrollment target
1
Study location

Study Summary

This study examines the safety of an app-based insulin bolus calculator that utilizes glucose values from a continuous glucose monitor.

Conditions Studied

Interventions

  • DEVICE BlueStar 10

Study Locations (1)

Maryland

  • MedStar Health Research Institute - Baltimore

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2022-07-05
Est. Completion 2022-12-20
Phase NA
Welldoc

2 total trials

What the finished NCT05343065 record still lists

NCT05343065 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which BlueStar 10 is the first listed.

NCT05343065 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT05343065 about?

NCT05343065 is a clinical study titled "A Continuous Glucose Monitor Based Insulin Bolus Calculator (CGM-IBC) Study B". This study examines the safety of an app-based insulin bolus calculator that utilizes glucose values from a continuous glucose monitor.

What is the current status of trial NCT05343065?

This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2022-07-05. Estimated completion is 2022-12-20.

What conditions does trial NCT05343065 study?

This clinical trial studies the following conditions: Diabetes Mellitus.

What interventions are being tested in trial NCT05343065?

The interventions under investigation include: BlueStar 10 (DEVICE).

Who is sponsoring clinical trial NCT05343065?

This trial is sponsored by Welldoc, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05343065 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05343065's enrollment target sits among peer trials

27 183rd of 208 higher than 26 of 208 other Diabetes Mellitus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00912041 · 27 participants · NA

    BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

  • NCT02847559 · 27 participants · Phase 2

    Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

  • NCT03380195 · 27 participants · NA

    Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness

  • NCT03384238 · 27 participants · Phase 1

    Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05343065, the US trial registry maintained by the National Library of Medicine. NCT05343065 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.